Kinase Inhibitor News and Research

RSS
A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.
New insights into how DAPK3 regulates the migration of triple-negative breast cancer cells

New insights into how DAPK3 regulates the migration of triple-negative breast cancer cells

New drug combo shows promise for deeper remission in chronic leukemia

New drug combo shows promise for deeper remission in chronic leukemia

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer

Zongertinib shows promising efficacy in HER2 mutation-positive NSCLC

Zongertinib shows promising efficacy in HER2 mutation-positive NSCLC

Taletrectinib shows high response rates and safety in ROS1+ lung cancer patients

Taletrectinib shows high response rates and safety in ROS1+ lung cancer patients

New dual kinase inhibitor MTX-531 shows promise in overcoming cancer therapy resistance

New dual kinase inhibitor MTX-531 shows promise in overcoming cancer therapy resistance

Researchers discover new target for treating diseases linked to T-cell leukemia virus type 1

Researchers discover new target for treating diseases linked to T-cell leukemia virus type 1

Live biotherapeutic product can improve clinical outcomes for patients with kidney cancer

Live biotherapeutic product can improve clinical outcomes for patients with kidney cancer

Causal variant-targeted ribonucleic acid treatment for congenital melanocytic nevi

Causal variant-targeted ribonucleic acid treatment for congenital melanocytic nevi

Combining anlotinib with STUPP regimen improves survival in glioblastoma patients

Combining anlotinib with STUPP regimen improves survival in glioblastoma patients

Existing drug alleviates symptoms of a rare genetic syndrome

Existing drug alleviates symptoms of a rare genetic syndrome

Targeting CD47 to improve osimertinib efficacy in EGFR mutant NSCLC

Targeting CD47 to improve osimertinib efficacy in EGFR mutant NSCLC

Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity

Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity

Combination therapy offers breakthrough in NSCLC treatment

Combination therapy offers breakthrough in NSCLC treatment

Hope for relapsed myeloma: Preclinical and clinical evidence for ruxolitinib's efficacy

Hope for relapsed myeloma: Preclinical and clinical evidence for ruxolitinib's efficacy

Pazopanib activity confirmed in EWSR1-NFATC2 bone sarcoma

Pazopanib activity confirmed in EWSR1-NFATC2 bone sarcoma

Glioblastoma tumor cells mimic neurons to evade treatment

Glioblastoma tumor cells mimic neurons to evade treatment

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

Targeted therapy reduces markers of disease burden, improves symptoms for patients with nonadvanced system mastocytosis

Fecal microbiota transplantation boosts survival in metastatic colorectal cancer treatment

Fecal microbiota transplantation boosts survival in metastatic colorectal cancer treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.